Protagonist Therapeutics (PTGX) Operating Expenses (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Operating Expenses data on file, last reported at $60.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 26.0% year-over-year to $60.0 million; the trailing twelve-month figure through Mar 2026 stood at $216.5 million (up 19.91% YoY), and the FY2025 full-year result was $204.1 million, up 12.42% from the prior year.
• Operating Expenses rose to $60.0 million in Q1 2026, from $57.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $60.0 million in Q1 2026 to a low of $32.3 million in Q3 2022.
• A 5-year average of $44.6 million and a median of $43.9 million in 2024 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 55.02% in 2022, while the deepest fall reached 26.94% in 2022.
• Tracing PTGX's Operating Expenses over 5 years: stood at $36.5 million in 2022, then grew by 1.19% to $37.0 million in 2023, then grew by 18.69% to $43.9 million in 2024, then surged by 31.77% to $57.8 million in 2025, then advanced by 3.85% to $60.0 million in 2026.
• Business Quant data shows PTGX's Operating Expenses at $60.0 million in Q1 2026, $57.8 million in Q4 2025, and $51.1 million in Q3 2025.